Related Experiment Videos
Hepatocyte growth factor in transgenic mice
1Second Department of Internal Medicine, Tottori University, School of Medicine, Yonago, Japan.
International Journal of Experimental Pathology
|April 8, 1999
Summary
Hepatocyte growth factor (HGF) in transgenic mice promotes liver regeneration and protects against liver injury. HGF also inhibits the development of hepatocellular carcinoma (HCC) in vivo, suggesting therapeutic potential for liver diseases.
Area of Science:
- Hepatology
- Molecular Biology
- Oncology
Background:
- Hepatocyte growth factor (HGF) is a key regulator of liver regeneration and development.
- The role of HGF in liver cancer and injury requires further in vivo investigation.
Purpose of the Study:
- To investigate the in vivo functions of HGF in liver regeneration, hepatocellular carcinoma (HCC) development, and liver injury.
- To assess the therapeutic potential of HGF for liver diseases.
Main Methods:
- Development of transgenic mice expressing HGF in the liver.
- Assessment of liver regeneration after partial hepatectomy.
- Generation of double transgenic mice (HGF/TGFα and HGF/c-myc) to study HCC development.
- Evaluation of liver protection against D-galactosamine (D-GalN)-induced injury.
Main Results:
- HGF transgenic mice exhibited doubled bromodeoxyuridine labeling indices and accelerated liver regeneration post-hepatectomy.
- HGF expression in double transgenic mice reduced tumor yield and incidence of hepatocellular adenoma (HCA) and HCC.
- HGF transgenic mice showed increased prostaglandin E2 (PGE2) production and protection against D-GalN-induced liver injury.
Conclusions:
- HGF promotes liver regeneration and protects against liver injury, partly through increased PGE2 production.
- HGF inhibits the growth and occurrence of HCC in vivo.
- HGF holds potential for therapeutic applications in human liver diseases.